cators of average glycemic control overthe prior 2 weeks and 3 months, respec-tively). It is important to note that thestudy was not designed to assess differ-ences among the various treatmentgroups. Across the different regimens, 28days of AC2993 resulted in fructosamineconcentrations approaching the upperlimit of normal (285 /H9262mol/l) and HbA 1c reductions of /H110110.9%. This clinically sig-